Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Number of items: 30.

Willis, MD and Robertson, NP 2019. Technology-assisted recovery of walking after spinal cord injury. Journal of Neurology 266 (4) , pp. 1046-1048. 10.1007/s00415-019-09227-x
Item availability restricted.
file

Brown, J. William L., Coles, Alasdair, Horakova, Dana, Havrdova, Eva, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Trojano, Maria, Lugaresi, Alessandra, Bergamaschi, Roberto, Grammond, Pierre, Alroughani, Raed, Hupperts, Raymond, McCombe, Pamela, Van Pesch, Vincent, Sola, Patrizia, Ferraro, Diana, Grand'Maison, Francois, Terzi, Murat, Lechner-Scott, Jeannette, Flechter, Schlomo, Slee, Mark, Shaygannejad, Vahid, Pucci, Eugenio, Granella, Franco, Jokubaitis, Vilija, Willis, Mark, Rice, Claire, Scolding, Neil, Wilkins, Alastair, Pearson, Owen R, Ziemssen, Tjalf, Hutchinson, Michael, Harding, Katharine, Jones, Joanne, McGuigan, Christopher, Butzkueven, Helmut, Kalincik, Tomas and Robertson, Neil 2019. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. Journal of the American Medical Association 321 (2) , pp. 175-187. 10.1001/jama.2018.20588

Harding, Katharine, Williams, Owain, Willis, Mark, Hrastelj, James, Rimmer, Anthony, Joseph, Fady, Tomassini, Valentina, Wardle, Mark, Pickersgill, Trevor, Robertson, Neil and Tallantyre, Emma 2019. Disease modifying therapy in MS: clinical outcomes of escalation versus early intensive treatment strategies. JAMA Neurology
Item availability restricted.
file

Willis, Mark D, Hope-Gill, Ben, Flood-Page, Patrick, Joseph, Fady, Needham, Ed, Jones, Joanne, Coles, Alasdair and Robertson, Neil P 2018. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis 24 (13) , 1779-`782. 10.1177/1352458518790391
file

Muller, Ilaria, Willis, Mark, Healy, Sarah, Nasser, Taha, Loveless, Samantha, Butterworth, Sara, Zhang, Lei, Draman Yusof, Mohd, Taylor, Peter, Robertson, Neil, Dayan, Colin and Ludgate, Marian 2018. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years. Thyroid 10.1089/thy.2018.0232
Item availability restricted.
file

Harding, Katharine, Anderson, Valerie, Williams, Owain, Willis, Mark, Butterworth, Sara, Tallantyre, Emma, Joseph, Fady, Wardle, Mark, Pickersgill, Trevor and Robertson, Neil 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25 , pp. 186-191. 10.1016/j.msard.2018.08.001
Item availability restricted.
file

Willis, M. D. and Robertson, N. P. 2018. Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease. Journal of Neurology 265 (8) , pp. 1950-1952. 10.1007/s00415-018-8963-z
file

Pariani, Nadia, Willis, Mark, Muller, Ilaria, Healy, Sarah, Nasser, Taha, McGowan, Anne, Lyons, Greta, Jones, Joanne, Chatterjee, Krishna, Dayan, Colin, Robertson, Neil, Coles, Alasdair and Moran, Carla 2018. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. Journal of Clinical Endocrinology & Metabolism 108 (8) , pp. 3010-3018. 10.1210/jc.2018-00359
Item availability restricted.
file

Alsaeed, Meshari, Harding, Katharine, Williams, O. H., Willis, Mark, Hrastelj, James, Tallantyre, Emma, Joseph, Fady, Wardle, Mark, Pickersgill, T. P. and Robertson, Neil 2018. Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry. European Journal of Neurology 25 (4) , pp. 701-704. 10.1111/ene.13571
file

Ved, Ronak, Cobbold, Naomi, Igbagiri, Kueniemugh, Willis, Mark, Leach, Paul and Zaben, Malik 2017. Online patient information on Vagus Nerve Stimulation: How reliable is it for facilitating shared decision making? Seizure - European Journal of Epilepsy 50 , pp. 125-129. 10.1016/j.seizure.2017.06.009
file

Harding, Katharine, Tilling, Kate, MacIver, Claire, Willis, Mark, Joseph, Fady, Ingram, Gillian, Hirst, Claire, Wardle, Mark, Pickersgill, Trevor, Ben-Shlomo, Yoav and Robertson, Neil 2017. Seasonal variation in multiple sclerosis relapse. Journal of Neurology 264 (6) , pp. 1059-1067. 10.1007/s00415-017-8485-0
file

Willis, Mark D. and Robertson, Neil P. 2017. Chronic traumatic encephalopathy: identifying those at risk and understanding pathogenesis. Journal of Neurology 264 (6) , pp. 1298-1300. 10.1007/s00415-017-8508-x
file

Kalincik, Tomas, Brown, J William L, Robertson, Neil, Willis, Mark, Scolding, Neil, Rice, Claire M, Wilkins, Alastair, Pearson, Owen, Ziemssen, Tjalf, Hutchinson, Michael, McGuigan, Christopher, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Alroughani, Raed, Pucci, Eugenio, Sola, Patrizia, Hupperts, Raymond, Lechner-Scott, Jeannette, Terzi, Murat, Van Pesch, Vincent, Rozsa, Csilla, Grand'Maison, François, Boz, Cavit, Granella, Franco, Slee, Mark, Spitaleri, Daniele, Olascoaga, Javier, Bergamaschi, Roberto, Verheul, Freek, Vucic, Steve, McCombe, Pamela, Hodgkinson, Suzanne, Sanchez-Menoyo, Jose Luis, Ampapa, Radek, Simo, Magdolna, Csepany, Tunde, Ramo, Cristina, Cristiano, Edgardo, Barnett, Michael, Butzkueven, Helmut and Coles, Alasdair 2017. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. The Lancet Neurology 16 (4) , pp. 271-281. 10.1016/S1474-4422(17)30007-8
file

Willis, Mark, Pearson, Owen, Illes, Zsolt, Sejbaek, Tobias, Nielson, Christian, Duddy, Martin, Petheram, Kate, van Munster, Casper, Killestein, Joep, Malmestrom, Clas, Tallantyre, Emma and Robertson, Neil 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neuroimmunology and Neuroinflammation 4 (2) , E320. 10.​1212/​NXI.​0000000000000320
file

Willis, Mark 2017. A clinical and immunological study of CD8+ T cells in multiple sclerosis. PhD Thesis, Cardiff University.
Item availability restricted.
filefile

Clement, Mathew, Pearson, James, Gras, Stephanie, Van den berg, Hugo, Lissina, Anya, Llewellyn-Lacey, Sian, Willis, Mark, Dockree, Tamsin, McLaren, James, Ekeruche-Makinde, Julia, Gostick, Emma, Robertson, Neil, Burrows, Scott, Price, David, Wong, Florence, Peakman, Mark, Skowera, Ania and Wooldridge, Linda 2016. Targeted suppression of autoreactive CD8+ T-cell activation using blocking anti-CD8 antibodies. Scientific Reports 6 , 35332. 10.1038/srep35332
file

Willis, Mark, Pickersgill, Trevor, Robertson, Neil, Lee, Richard W. J., Dick, Andrew D. and Carreño, Ester 2016. Alemtuzumab-induced remission of multiple sclerosis-associated uveitis. International Ophthalmology 10.1007/s10792-016-0370-9
file

Willis, Mark and Robertson, Neil 2016. Alemtuzumab for multiple sclerosis. Current Neurology and Neuroscience Reports 16 , 84. 10.1007/s11910-016-0685-y
file

Willis, Mark, Harding, Katharine, Pickersgill, T., Wardle, Mark, Pearson, O., Scolding, N., Smee, J. and Robertson, Neil 2016. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Multiple Sclerosis Journal 22 (9) , pp. 1215-1223. 10.1177/1352458515614092
file

Healy, Sarah, Willis, Mark and Robertson, Neil Patrick 2015. Prognosis in multiple sclerosis and the unveiling of pathogenic clues. Journal of Neurology 262 (11) , pp. 2596-2598. 10.1007/s00415-015-7938-6

Willis, Mark, Harding, Katharine, Wardle, M., Pickersgill, T. P., Tomassini, Valentina, Loveless, Samantha and Robertson, Neil 2015. Site-specific clinical disease onset in multiple sclerosis. European Journal of Neurology 22 (4) , pp. 732-735. 10.1111/ene.12564

Willis, Mark and Robertson, Neil 2015. Alemtuzumab for the treatment of multiple sclerosis. Therapeutics and Clinical Risk Management 2015 (11) , pp. 525-534. 10.2147/TCRM.S80112

Hirst, C. L., Willis, Mark, Hussain, H. and Powell, R. 2015. Acute myeloid leucaemia presenting as a rapidly progressive polyradiculoneuropathy. BMJ Case Reports 2015 , bcr2015209556. 10.1136/bcr-2015-209556

Willis, Mark and Robertson, Neil 2014. Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opinion on Drug Safety 13 (8) , pp. 1115-1124. 10.1517/14740338.2014.928691

Willis, Mark, Jones, L., Vincent, A., Wheeler, R., O'Callaghan, P. and Hamandi, Khalid 2014. VGKC-complex antibody encephalitis. Qjm -Oxford- 107 (8) , pp. 657-659. 10.1093/qjmed/hcu030

Willis, Mark and Robertson, Neil 2014. Treatment paradigms in multiple sclerosis: who, when and how to treat? Journal of Neurology 261 (7) , pp. 1444-1446. 10.1007/s00415-014-7420-x

Willis, Mark, Amato-Watkins, T., Zaben, M., Baig, A., Corkill, R. and Joshi, Y. 2014. Reversible brainstem dysfunction from spinal arterio-venous fistula. Practical Neurology 14 (6) , pp. 425-428. 10.1136/practneurol-2014-000872

Willis, Mark and Robertson, Neil 2013. Amyotrophic lateral sclerosis: new hope for an old disease? Journal of Neurology 260 (9) , pp. 2441-3. 10.1007/s00415-013-7063-3

Willis, Mark, Rudge, P and Walters, RJ 2013. Subacute sclerosing panencephalitis: rapidly progressive cognitive decline in a young patient. British Journal of Hospital Medicine 74 (3) , pp. 172-173. 10.12968/hmed.2013.74.3.172

Willis, Mark and Robertson, Neil 2012. Aphasia: early classification, evaluation of existing therapy, and novel therapeutics. Journal of Neurology 259 (11) , pp. 2510-2512. 10.1007/s00415-012-6701-5

This list was generated on Thu Mar 21 04:24:54 2019 GMT.